News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TrovaGene, Inc. Announces that its NPM1 Technology is Now Part of Laboratory Corporation of America Holdings (LabCorp) (LH)'s and InVivoScribe Technologies, Inc.'s AML Cancer Testing Services


3/31/2010 11:24:23 AM

SAN DIEGO--(BUSINESS WIRE)--TrovaGene, Inc. (TROV.PK), formerly Xenomics, Inc. (XNOM.PK), a developer of transrenal molecular diagnostics, announced today that LabCorp, one of the world’s leading reference laboratories, (LabCorp, NYSE:LH), and InVivoScribe Technologies, a world leader in molecular hematopathology testing, have notified the Company that they have begun laboratory testing services for the detection of NPM1 mutations for the diagnosis of acute myelogenous leukemia (AML). TrovaGene has sublicensed the technology to these labs and will receive royalties based upon their testing revenue.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES